Kinase Inhibitors: Global Markets
The global market for kinase inhibitors should grow from $57.6 billion in 2021 to $79.2 billion by 2026 with a compound annual growth rate (CAGR) of 6.6% for the period of 2021-2026.
- 27 data tables and 28 additional tables
- An overview of the global markets for kinase inhibitors
- Estimation of the market size and analyses of global market trends, with data from 2019, 2020 estimates for 2021 and projections of compound annual growth rates (CAGRs) through 2026
- Identification of market drivers, restraints and other forces impacting the global market and evaluation of current market size and forecast and technological advancements within the industry
- Information on enzyme inhibitors, kinase inhibitors and classification by types of amino acid & phosphorylation
- Analysis of pipeline products and kinase inhibitors related patents, and comparative description of multiple single kinase inhibitors versus single multikinase inhibitors in terms of efficacy, resistance and pharmacokinetics
- Market share analysis of the key companies of the industry and coverage of events like mergers & acquisitions, joint ventures, collaborations or partnerships, and other key market strategies
- Company profiles of major players, including Pfizer, Novartis AG, AstraZeneca, Bayer AG, Eisai Co. Ltd. and Johnson & Johnson
This BCC Research report is designed to be a business tool that will provide a thorough evaluation of the markets for kinase inhibitors. The geographical scope of this study is global. Various types of kinase inhibitors have been analyzed in the report, and along with their different application scenarios, the scope of this study includes regulatory aspects, pipeline analysis and demand for kinase inhibitors. The report discusses market shares of kinase inhibitors based on type, application and geography.
Based on type, the market is segmented into tyrosine kinase inhibitors and serine/threonine kinase inhibitors. Tyrosine kinase inhibitors are further segmented into receptor and non-receptor tyrosine kinase inhibitors.
Based on application, the market is segmented into antineoplastic agents, age-related molecular degeneration (AMD) and immunosuppressants.
By geography, the market has been segmented into North America, Europe, Asia-Pacific, and Rest of the World. Analyses of the markets of major countries such as the U.S., Canada, Germany, the U.K., France, Spain, Italy, Japan, China, and India are covered in regional segments. For market estimates, data has been provided for the year 2020 as the base year, with forecasts for 2021 through 2026. Estimated values used are based on drug manufacturers’ total revenues. Projected and forecasted revenue values are in constant U.S. dollars, unadjusted for inflation.
BCC Publishing Staff comprises expert analysts who are skilled in conducting primary research, secondary research and data analysis and have decades of combined experience covering a wide range of industries, including healthcare, advanced materials and emerging technologies. Collectively, the team represents a diverse set of educational achievements with individual graduate work completed in fields such as microbiology, electrical engineering, business administration and surgery, among others.
The global kinase inhibitors market reached $28.1 billion in 2010 and nearly $29.1 billion in 2011. The market is expected to reach $40.2 billion by 2016, a compound annual growth rate (CAGR) of 6.7%.
- Overall sales in the global market for kinase inhibitors were nearly $14 billion in 2008 which increased to $15.2 billion in 2009. By 2014, it is estimated to increase to $20.2 billion, at 5 year compound annual growth rate (CAGR) of 5.8%.
- The largest segment receptor tyrosine kinase inhibitors market was nearly $9.4 billion in 2008; which increased to $10 billion in 2009. This is expected to rise to $13.1 billion in 2014, a CAGR of 5.5%.
- Sales in serine/threonine kinase inhibitors (STKIs) reached approximately $512 million in 2008. This further increased to $855 million in 2009 and is projected to reach $1.4 billion in 2014, at a CAGR of 10.7%.
The worldwide market for kinase inhibitors for clinical use will reach $4.63 billion in 2005 and will rise at an average annual growth rate (AAGR) of 20.6% to $11.8 billion by 2010.
Receptor tyrosine kinase inhibitors comprise 49.8% of the total market in 2005 and are projected to grow at an AAGR of 26.6% to account for 63.7% of the total in 2010.
Nonreceptor tyrosine kinase inhibitors, consisting of BCR-Abl kinase inhibitor, reached sales of $1.86 billion in 2005. They are projected to increase at an AAGR of 13.7% to reach $3.56 billion in 2010.
The major disease application for kinase inhibitors is oncology that comprised nearly 90% of kinase inhibitor sales in 2005 and is expected to grow at an AAGR of 21.5%.